Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 3

2(40.0%)

5Total

Phase 2(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05889845Phase 3Completed

Candin for the Treatment of Common Warts

Role: lead

NCT01757392Phase 2Completed

Candin Safety & Efficacy Study for the Treatment of Warts

Role: lead

NCT02393417Phase 2Completed

Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

Role: lead

NCT00633009Phase 2Completed

Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen

Role: lead

NCT00690092Phase 3Completed

A Multi-center Study of Spherule-Derived Coccidioidin

Role: lead

All 5 trials loaded